IDEX Corporation (NYSE: IEX) saw its stock price surge 5.33% in pre-market trading on Thursday following the release of its better-than-expected first-quarter 2025 financial results. The industrial manufacturing company reported earnings and revenue that exceeded Wall Street estimates, driven by strong performance across all its business segments.

For the quarter ended March 31, IDEX reported adjusted earnings per share of $1.75, surpassing the analyst consensus estimate of $1.63. This represents a 7.36% beat, despite a 6.91% decrease from the $1.88 per share reported in the same period last year. The company's revenue for the quarter came in at $814.3 million, beating the analyst estimate of $807.2 million by 0.88% and showing a 1.72% increase from the $800.5 million reported in the prior-year quarter.

Eric Ashleman, IDEX Corporation President and Chief Executive Officer, commented on the results, saying, "Our IDEX teams delivered better than expected revenue and profitability in the first quarter of 2025, with all segments exceeding our expectations." He highlighted the strong performance of the Health & Science Technologies segment, which saw a 10% increase in net sales, primarily driven by the recent acquisition of Mott Corporation.

Looking ahead, IDEX maintained its full-year 2025 guidance, projecting organic sales growth of 1% to 3% and adjusted earnings per share between $8.10 and $8.45. The company also announced additional cost containment actions, targeting $20 million in savings to mitigate potential tariff-related volume pressures. This proactive approach has been well-received by investors, contributing to the stock's positive momentum.

Analysts remain optimistic about IDEX's prospects, with some seeing significant upside potential for the stock. The company's focus on strategic acquisitions, strong cash flow generation, and diverse portfolio of engineered products across various industries position it well for future growth. As IDEX continues to navigate global economic challenges and capitalize on opportunities in key markets such as life sciences and clean water technology, investors will be closely watching its performance in the coming quarters.